Hasani, A et al. Chron Respir Dis 5, no. 2 (2008): 81-86.
Roca, O et al. Respir Care 55, no. 4 (2010): 408-413.
*FDA cleared for use in hospitals and long term facilities. Available for home care use in the US under COVID-19 provisions.
Use of High-Flow Nasal Therapy on Patients with Suspected or Confirmed COVID-19 COVID-19 is a highly contagious disease, and virtually all forms of respiratory support, including high-flow nasal therapy, pose some risk of disease transmission. The U.S. Food and Drug Administration has stated that ventilating patients with communicable diseases using noninvasive devices without a filtered seal from atmosphere may contaminate room air and increase risk of transmission, and that this risk may be exacerbated by high-flow nasal therapy systems. Some clinicians have also suggested that the use of high flow nasal therapy may facilitate the spread of COVID-19 or other communicable diseases through aerosolization of pathogens. If high-flow nasal therapy is used to treat patients with COVID-19 or other communicable diseases, appropriate precautions should be taken, such as placing a mask over the nose and mouth of suspected and infected patients while on high-flow nasal therapy, isolating patients in negative pressure rooms, and providing caregivers with appropriate personal protective equipment specified for aerosol-generating procedures; however, these precautions cannot guarantee that diseases will not be transmitted to caregivers or others.
For professional use. See instructions for use for full prescribing information including indications, contraindications, warnings and precautions.
Submit a request to receive more information and a Masimo representative will contact you shortly.